At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
afegostat tartratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Long-Term Extension Study To Assess The Safety, Efficacy, And Pharmacodynamics Of AT2101 In Adult Patients With Type 1 Gaucher Disease
In Brief
A Phase 2 clinical trial evaluating afegostat tartrate for Gaucher Disease and 2 related conditions. Completed, enrolled 8 participants across 4 sites in 2 countries.
Detailed Summary
This study evaluated the long-term safety and efficacy of afegostat tartrate in participants with Gaucher disease who were enrolled in a previous Phase 2 study of afegostat tartrate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartMay 2009
Primary CompletionMay 2012
TodayJul 2026
First PostedDec 23, 2008
Enrollment StartMay 11, 2009
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 17.5 years ago
Interventions
afegostat tartratedrug